Deutsche Bank Upgrade Lifts Merck Shares as Analyst Sees Clear Path Beyond Keytruda
Merck shares climbed after Deutsche Bank elevated the stock to Buy with a $150 price target, arguing the market is underpricing the company amid concerns about Keytruda's patent expiry. The bank projects a trough earnings level above Street consensus and highlights acquisitions and pipeline potential that could offset revenue pressure from Keytruda…